CJC-1295 (No DAC) + Ipamorelin protocol

Standard

Weeks 1–2

6.0u

200 mcg · Nightly pre-bed

Start low and assess how your body responds before increasing.

Weeks 3–12

12.0u

400 mcg · Nightly pre-bed

Standard effective dose for most users.

Off

4 weeks

Off period, let your pituitary and receptors recover before the next cycle.

Phase	How often	Dose	Units	Notes
Weeks 1–2	Nightly pre-bed	200 mcg	6.0u	Start low and assess how your body responds before increasing.
Weeks 3–12	Nightly pre-bed	400 mcg	12.0u	Standard effective dose for most users.
Off	4 weeks	–	–	Off period, let your pituitary and receptors recover before the next cycle.

Cycle & timing

Cycle: 12 weeks on / 4 weeks off. Max 16 weeks on / 4–8 weeks off; receptor desensitization beyond 16 weeks continuous.

Timing: Fasted, pre-bed is standard; the pulse lands with the natural deep-sleep GH release, which is why this stack is the go-to for sleep + recovery. No food 90 min before / 60 min after; fasted AM works if pre-bed is impractical.

Where: Abdomen. Single injection delivers both.

What to expect

Improved sleep depth within 1–2 weeks. Recovery and energy improvement at 4–6 weeks. Body composition changes at 8–12 weeks.

How much to buy

For 12-wk @ 400 mcg × 7/wk:

4

× 10mg vials

Men & women

Men: Men convert GH to IGF-1 more efficiently and more often overshoot the age ceiling (a higher malignancy signal), aim mid-normal for age, don't chase the top.

Women: Women make ~3× the GH of men yet have similar IGF-1, they're less responsive, so often need a higher dose to move IGF-1. Oral estrogen blunts IGF-1 further (read it as running low); a skin patch/gel is more predictable.

Dilution calculator

Set to the guide's typical mix for CJC-1295 (No DAC) + Ipamorelin. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

12u

Volume

0.12 mL

Strength

3.33 mg/mL

Doses per vial

25

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
10 mg	3 mL	3.33 mg/mL

10 mg: 1 unit = 0.03 mg

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, use within 4 weeks.

Don't use if: Active malignancy of any kind (GH/IGF-1 can promote tumor growth) · Severe diabetic retinopathy · Acute critical illness (per somatropin label, applies to GH-axis stimulators) · Pregnancy and lactation

Stop if you notice

Fasting glucose rises >20 mg/dL above baseline
IGF-1 rises above the upper limit of normal for age
New persistent joint pain or carpal tunnel symptoms
New skin changes or moles enlarging
Vision changes

Side effects

Water retention, mild fatigue, tingling.

Drug interactions

Glucocorticoids: blunt GH response, minimize or time away from injection. Insulin / antidiabetics: GH worsens insulin resistance, expect dose adjustments + tighter monitoring. Levothyroxine: GH lowers free T4, recheck TSH/fT4 quarterly. Oral estrogens: blunt GH-stimulated IGF-1, transdermal doesn't. CYP3A4 narrow-TI substrates (cyclosporine, tacrolimus, sirolimus): recheck troughs after starting.

Labs

Compound-specific: IGF-1 (baseline + Week 8 + end), Lipid panel (Week 0/12). IGF-1 at baseline, mid-cycle, and end of cycle. Target ULN for age. Fasting glucose and HbA1c at baseline and end of cycle. Mammogram and prostate screening per age-appropriate guidelines before starting. Out of range? IGF-1 above your age range = too much growth signal (feeds hidden cancer, enlarges organs) → drop the dose; rising glucose/HbA1c = sugar creeping up.

What these labs mean →

Warnings

Insulin resistance and worsening glycemic control with sustained use. Fluid retention, peripheral edema. Carpal tunnel syndrome with extended use. Joint and muscle pain. IGF-1 elevation: theoretical malignancy promotion if dosed beyond physiological IGF-1 ranges. Combined GHRH+GHRP use requires off cycles to prevent receptor desensitization.

Patient education

GH-axis stimulation is not appropriate during active malignancy or for fertility. Most GH pulses occur during deep sleep, dose pre-bed unless instructed otherwise. Food within 90 min of injection blunts GH response (carbs/fats most), fasted is standard. Report new lumps, persistent headaches, or vision changes immediately.

These apply on top of the universal safety rules.

Pairs well with

BPC-157 / TB-500

tissue repair on GH backbone

BPC-157 TB-500 (Thymosin Beta-4)

IGF-1 LR3

downstream amplification

IGF-1 LR3

Avoid with

Active malignancy

Type 2 diabetes without monitoring

GH worsens insulin resistance

Can CJC-1295 (No DAC) + Ipamorelin + BPC-157 share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

What it does

Somatropin (HGH) is approved for growth-hormone deficiency and tesamorelin (Egrifta) for HIV lipodystrophy. Secretagogues like this one are off-label.

Pre-mixed GHRH + GHRP stack, amplified, synergistic GH pulse from two different receptor pathways in one injection. CJC-1295 (No DAC) stimulates GHRH receptors. Ipamorelin activates GHS-R1a ghrelin receptors.

Sleep

GHRH promotes slow-wave sleep, most notice deeper sleep in 1–2 weeks.

References

peptidedosages PubMed thepeptidereport Span 2000 Weissberger 1991

From the guide, page 28.